Neutropenia represented the most frequent hematologic side effect of CDK4/6 inhibitors treatment; however, for only 5% of respondents neutropenia was a relevant cause of treatment discontinuation for the outcome (Figure 2). This evidence concerns the gene CDK4 and neutropenia.